Hot Topics: Current Barriers to Myeloid Therapy

Recent discussions in neuro-oncology highlight the evolving role of myeloid cells in the treatment of glioblastoma (GBM). Amy Heimberger, a leading researcher in the field, emphasizes that myeloid cells, once considered merely immunosuppressive bystanders, are now recognized as potential therapeutic targets. This shift in understanding is largely attributed to advancements in single-cell sequencing, which has allowed researchers to better classify and understand the diverse functions of myeloid cells within the tumor microenvironment.

Despite promising preclinical findings, translating myeloid cell therapies into clinical practice remains challenging. Heimberger identifies tumor heterogeneity, myeloid plasticity, and other microenvironmental factors as significant barriers. She notes that the biology of myeloid cells can vary greatly depending on the tumor's molecular characteristics, such as IDH mutation status, and that interactions between myeloid cells and tumor cells differ based on their spatial distribution within the brain.

Looking ahead, Heimberger suggests that future research should focus on developing tailored therapeutic strategies that consider the unique characteristics of each patient's tumor. She advocates for the use of combination therapies and the identification of relevant biomarkers to optimize patient selection for myeloid-targeted treatments. As the field progresses, there is hope that innovative approaches will enhance the effectiveness of therapies for GBM and improve patient outcomes.

Dr. Daniel Zamler interviews Dr. Amy Heimberger on the current limitations to myeloid therapy- specific discussions include combination therapies, plasticity of myeloid cells, translation, patient stratification and outlook. Podcast Host and Interviewee: Host: Dr. Daniel Zamler Interviewee: Dr. Amy Heimberger